# EDGAR Filing Document

**Accession Number:** 0001856725
**File Stem:** 0001193125-25-178946
**Filing Date:** 2025-8
**Character Count:** 2986
**Document Hash:** eb7d47e6c0e392de6c118336e95faa61
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-178946.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001193125-25-178946

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rani Therapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001856725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2051 RINGWOOD AVENUE
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95131
- **BUSINESS PHONE:** (408) 457-3700

**MAIL ADDRESS:**
- **STREET 1:** 2051 RINGWOOD AVENUE
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95131

RANI THERAPEUTICS HOLDINGS, INC.

2051 Ringwood Avenue

San Jose, California 95131

August 12, 2025

***VIA EDGAR***

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Chris Edwards

---

| | |
|:---|:---|
| **Re:** | **Rani Therapeutics Holdings, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-289424** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Acceleration Request** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Acceleration Request** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Acceleration Request** |
|  | **Requested Date:** | **August 14, 2025** |
|  | **Requested Time:** | **4:15 PM Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Rani Therapeutics Holdings, Inc. (the "***Company***") hereby requests that the Securities and Exchange Commission (the "***Commission***") accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the "***Registration Statement***") and declare the Registration Statement effective as of 4:15 p.m. Eastern Time, on August 14, 2025, or as soon thereafter as possible, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. The Company hereby authorizes each of Josh Seidenfeld and John McKenna of Cooley LLP, counsel to the Company, to make such a request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP at (650) 843-5059.

[Signature page follows]

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Rani Therapeutics Holdings, Inc. | Rani Therapeutics Holdings, Inc. |
| /s/ Svai Sanford | /s/ Svai Sanford |
| By: | Svai Sanford |
| Title: | Chief Financial Officer |

---

cc:

Josh Seidenfeld, Cooley LLP

John McKenna, Cooley LLP

[Signature Page to Acceleration Request]